AIM
BLCM

Advantage Investment Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Advantage Investment Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20
Closed -$4K – 916
2015
Q2 		$4K Buy
+20
New +$4.9K ﹤0.01% 729

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advantage Investment Management's BLCM Position: Q3 2015 in Review

Advantage Investment Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2015, closing a stake of 20 shares — an estimated $4K sold.

Advantage Investment Management first reported a position in BLCM in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 83 funds tracked by Wall St. Rank hold BLCM as of Q3 2015.

  • Advantage Investment Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Advantage Investment Management sold 20 Bellicum Pharmaceuticals, Inc. shares in Q3 2015, an estimated $4K.
  • Advantage Investment Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Advantage Investment Management's Bellicum Pharmaceuticals, Inc. position peaked at $4K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2015.

Based on Advantage Investment Management's 13F filing for Q3 2015, filed 27 Mar 2017.